FDA Clears At-Home Leqembi Injections for Early Alzheimer’s

Developed by BioArctic and its partner Eisai, the new delivery method allows patients to initiate and maintain therapy from home. The approved regimen requires 500 mg weekly, split into two 15-second injections. This approval expands the utility of the anti-amyloid treatment, which remains indicated for adults with mild cognitive impairment or mild dementia associated with the disease.

Clinical data from the Phase 3 Clarity AD long-term extension study confirmed that subcutaneous administration achieves drug exposure equivalent to intravenous dosing, maintaining consistent efficacy and biomarker benefits. Safety profiles between the two methods were found to be comparable, with localized injection-related reactions occurring more frequently than systemic ones. By reducing the necessity for clinic visits and infusion center resources, the autoinjector aims to simplify the care pathway for both patients and their caregivers. According to recent acceptability studies, 94% of participants reported ease of use and high confidence in managing the device independently.